Program
darovasertib
Also written as “Darovasertib”, “IDE196” and “LXS196”.
Its studies are mostly in Uveal Melanoma, led by 2 companies.
Furthest: phase 3, since Jul 12, 20236 company-led studies, 5 open or runningNext primary completion: Jan 15, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| IDEAYA Biosciences | 55 open or running | phase 3since Jul 12, 2023 | May 9, 2019 | Jan 15, 2027phase 3 · NCT05987332 |
| Novartis | 10 open or running | phase 1since Nov 6, 2015 | Nov 6, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2015First study: phase 1 study in Uveal MelanomaNew to NovartisNovartis · NCT02601378 · 107 enrolled · United States, Australia, France and more
- May 9, 2019IDEAYA Biosciences's first study: phase 2 study in Uveal MelanomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT03947385 · 336 planned · United States, Australia, Canada
- Jun 6, 2023Phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT05907954 · 160 enrolled · United States, Australia, Canada and more
- Jul 12, 2023Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT05987332 · 420 enrolled · United States, Australia, Belgium and more
- Jun 3, 2025Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07015190 · 520 planned · United States, Australia, Austria and more
- Aug 21, 2026Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07804186 · 450 planned · United States, Australia, Canada and more
Ahead
- Jan 15, 2027Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT05987332
- Jan 29, 2027Primary completion: phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT03947385
- Apr 30, 2027Primary completion: phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT05907954
- Oct 2030Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07015190
TargetBeta
PRRT2 →read by rule
“An orally available protein kinase C (PKC) inhibitor ”NCIt, by rule
Other programs on PRRT2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| PKC-beta Inhibitor MS-553rule | mingsight-pharmaceuticals-inc | phase 2 | 6 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07804186Uveal Melanoma · United States, Australia, Canada and more | 3 | Recruiting | IDEAYA Biosciences | Mar 2034 | 450 |
| NCT07015190Uveal Melanoma · United States, Australia, Austria and more | 3 | Recruiting | IDEAYA Biosciences | Oct 2030 | 520 |
| NCT05987332Uveal Melanoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | IDEAYA Biosciences | Jan 15, 2027 | 420 |
| NCT05907954Uveal Melanoma · United States, Australia, Canada and more | 2 | Active, not recruiting | IDEAYA Biosciences | Apr 30, 2027 | 160 |
| NCT03947385Uveal Melanoma · United States, Australia, Canada | 2 | Recruiting | IDEAYA Biosciences | Jan 29, 2027 | 336 |
| NCT02601378Uveal Melanoma · United States, Australia, France and more | 1 | Terminated | Novartis | Jan 7, 2022 | 107 |
How it is read
Names in the registry
- “Darovasertib”, 3 entries
- “IDE196”, 2 entries
- “LXS196”, 1 entry
- “LXS196 and HDM201”, 1 entry
Conditions, from the studies’ own filings
- Uveal Melanoma, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.